This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"I think it's really important, as we move to 2026 and beyond, we figure out ways to help pharmacies ease that burden and diversify their business." Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patientcare tips. Subscribe Now!
The Immunization Action Coalition also has a travel vaccine section on its website with many resources. Depending on the pharmacy practice act for your state, you may or may not be able to provide all vaccinations recommended by the Advisory Committee on Immunization Practices. 2026 Edition. The Immunization Action Coalition.
Positive results have been announced from a phase 2a clinical trial evaluating the safety, pharmacokinetics and efficacy of PP405 for the treatment of androgenetic alopecia in adult patients, Pelage Pharmaceuticals announced in a release. 1 The company said it plans to initiate phase 3 studies in 2026 to further evaluate the therapy.
Payers are eager to engage pharmacies in driving better patientcare and outcomes, but for this effort to be successful, consistent and reliable methods are needed to measure pharmacists contributions to care. Results from this two-year project will be shared in 2026.
The FDA has accepted for review a New Drug Application (NDA) for doravirine/islatravir for adult patients with HIV-1 infection that is virologically suppressed on antiretroviral therapy, Merck announced in a release. 1 The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026. References 1. Subscribe Now!
With rising drug costs, evolving health care regulations, and challenging reimbursement models, pharmacies must adopt strategic approaches to maintain financial health and continue providing patientcare.
1 The Advisory Committee on Immunization Practices voted to lower the pneumococcal recommendation to 50 years in October 2024. Previously, the vaccination recommendation was for patients 65 years and older, but the CDC Advisory Committee on Immunization Practices (ACIP) voted to lower the recommendation to 50 years in October 2024.
Merck said in the release that it anticipates ordering of clesrovimab-cfor to begin in July, with shipments being delivered before the start of the 2025-2026 RSV season. Stay ahead of the curve: Sign up for our free Drug Topics newsletter and get the latest drug information, industry trends, and patientcare tips, straight to your inbox.
All graduates should be ready for this, as our present Accreditation Council for Pharmacy Education Standards explicitly states: "Ensure that graduating students are ‘practice-ready’ and ‘team-ready,’ that is, prepared to directly contribute to patientcare working in collaboration with other health care providers."
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content